Pfizer Restructures For A More Flexible Future
Executive Summary
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets
You may also be interested in...
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
At the forefront of radical R&D reorganization, GlaxoSmithKline continues to evolve its model, characterized to date by the breaking up of R&D into small, biotech-like drug performance units (DPUs). These units are about to undergo the latest round of change: closer integration with the downstream medicines development centers in their respective therapeutic areas. The move makes sense given industry's growing recognition of the need for payor and regulator requirements to inform even early-stage discovery and development.
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
At the forefront of radical R&D reorganization, GlaxoSmithKline continues to evolve its model, characterized to date by the breaking up of R&D into small, biotech-like drug performance units (DPUs). These units are about to undergo the latest round of change: closer integration with the downstream medicines development centers in their respective therapeutic areas. The move makes sense given industry's growing recognition of the need for payor and regulator requirements to inform even early-stage discovery and development.
R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D
Pfizer in turn appoints Mikael Dolsten, an ex-Wyeth executive, as its worldwide R&D president.